The ASCO Post Podcast

This week, we present reports on four important presentations made during the American Association for Cancer Research (AACR) Annual Meeting, focusing on novel inhibitory therapeutics; adjuvant immunotherapy for patients with hepatocellular carcinoma at high risk of recurrence; the effect of treatment protocols guided by precision medicine on survival for patients with relapsed or refractory cancer; and community engagement for clinical trial recruitment. To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we are sharing news presented during the American Association for Cancer Research (AACR) Annual Meeting, which was held earlier this month in Orlando. We feature three researchers discussing their findings in non–small cell lung cancer, early-stage breast cancer, and solid tumors harboring DNA damage response alterations.To listen to more podcasts from ASCO, visit asco.org/podcasts.

The National Comprehensive Cancer Network, or NCCN, held its annual meeting recently in Orlando. On this week's episode of The ASCO Post podcast, we'll hear from two presenters who discussed quality of life issues in individuals with cancer.To listen to more podcasts from ASCO, visit asco.org/podcasts.

The National Comprehensive Cancer Network, or NCCN, held its annual meeting recently in Orlando. On this week's episode, we'll hear from two of the presenters who discussed NCCN Clinical Practice Guidelines Updates in chronic lymphocytic leukemia/small lymphocytic lymphoma and CNS cancers in adults. We'll also hear about a third presentation on the molecular landscape of metastatic colorectal cancer and its treatment.To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we discuss two important studies presented over the past month at two oncology meetings, including the Society of Gynecologic Oncology Annual Meeting on Women's Cancer and the Miami Breast Cancer Conference.To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we discuss two studies that were presented at the Society of Surgical Oncology (SSO) 2023 International Conference on Surgical Cancer Care. First, we'll share results of the SWOGS1512 study of neoadjuvant pembrolizumab in patients with stage II to III desmoplastic melanoma. Then, we'll hear about a study which aimed to evaluate whether personalized ctDNA profiling could aid in identifying recurrence in patients with soft-tissue sarcomas.To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we are recognizing colorectal cancer awareness month with two news items pertaining to gastrointestinal oncology reported over the past week. To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this week's episode, we're continuing our coverage of data presented at the 2023 ASCO Genitourinary Cancers Symposium in San Francisco. Daniel Petrylak, MD, and Matt Galsky, MD, discuss two separate studies in urothelial carcinoma. Following this, in recognition of International Women's Day, we'll hear from Isabel Rubio, MD, PhD, President of the European Society of Surgical Oncology. Dr. Rubio shares some of the efforts being made by the Society to help encourage women to pursue a career in surgical oncology as well as leadership roles in oncology.To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we're continuing our coverage of data presented at the 2023 ASCO Genitourinary Cancers Symposium, which took place recently in San Francisco. We'll hear from three researchers about their findings in prostate cancer trials reported at the meeting.To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we're sharing news from our coverage of data presented at the 2023 ASCO Genitourinary Cancers Symposium, which took place recently in San Francisco. We'll hear from two researchers about their findings in renal cell carcinoma (RCC).To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we're reviewing two recent U.S. Food and Drug Administration (FDA) approvals for patients with breast cancer: the February 3 approval of sacituzumab govitecan-hziy, and the January 27 approval of elacestrant.To listen to more podcasts from ASCO, visit asco.org/podcasts.

The 2023 ASCO Gastrointestinal Cancers Symposium took place from January 19 to 21 in San Francisco. On this episode, we're hearing from the presenting authors of three studies reported at that meeting—the SUNLIGHT, SPOTLIGHT, and NAPOLI-3 trials—which examined novel regimens in colorectal cancer, gastric cancer, and pancreatic cancer, respectively.To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, Chandrakanth Are, MBBS, MBA, FSSO, FRCS, FACS, Professor of Surgical Oncology and Global Health at University of Nebraska Medical Center, and an editorial advisor for The ASCO Post, holds a conversation with John H. Strickler, MD, a medical oncologist at Duke University Medical Center. The topic is the safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously treated patients with KRAS G12C–mutated pancreatic cancer, based on Strickler et al's paper published on January 5th in The New England Journal of Medicine.Coverage of stories discussed this week on ascopost.com:Sotorasib in Previously Treated Patients With KRAS G12C–Mutated Advanced Pancreatic CancerTo listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we're continuing our coverage of research presented at the 2022 ASH Annual Meeting and Exposition. Today, we'll hear from several researchers about their findings in lymphoma.To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we're continuing our coverage of research presented at the 2022 ASH Annual Meeting and Exposition. Today, we'll hear from several researchers about their findings in multiple myeloma. To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we're featuring authors discussing their impactful research presented at the 2022 ASH Annual Meeting and Exposition, focusing on findings in different subtypes of leukemia.To listen to more podcasts from ASCO, visit asco.org/podcasts.

This year's San Antonio Breast Cancer Symposium took place last week. On this episode, we're hearing from the authors of three high-impact studies that were presented at the meeting.To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we're reviewing U.S. Food and Drug Administration (FDA) approvals in oncology and hematology that occurred during the month of November.To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we're hearing from three authors of high-impact research that was presented at the recent Annual Meeting of the Society for Immunotherapy of Cancer, or SITC. Their studies focused on immune checkpoint inhibitors for patients living with HIV and cancer, T-cell receptor T-cell therapy for patients with solid tumors, and radiation boosts plus pembrolizumab in patients with triple-negative breast cancer.To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we're hearing from authors of recent impactful research in the field of genitourinary oncology. To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we're covering two recent approvals from the U.S. Food and Drug Administration (FDA): one in unresectable hepatocellular carcinoma, and one in relapsed or refractory multiple myeloma.To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we're covering two studies that focused on the effects of mortgage discrimination on cancer care outcomes. The research—in colon and lung cancers—was presented during the 2022 ASCO Quality Care Symposium.To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we're highlighting speakers who presented data in skin cancers during the ESMO Congress 2022, including findings on tumor-infiltrating lymphocyte therapy in advanced melanoma, cemiplimab in cutaneous squamous cell carcinoma, and the association of circulating tumor DNA and disease recurrence in patients with later-stage melanoma.To listen to more podcasts from ASCO, visit asco.org/podcasts.

The 2022 ASCO Quality Care Symposium took place in Chicago over the weekend. On this episode, we're featuring two speakers who presented data at the meeting: the first focuses on the effects of Medicaid expansion on cancer mortality rates, and the second describes efforts to improve prescribing practices for prophylactic colony stimulating factors in the treatment of neutropenia.To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we're highlighting speakers who presented data in breast cancer during the ESMO Congress 2022. The first speaker discusses patterns of genomic instability in metastatic breast cancer, and the second touches on oncofertility care for young patients with breast cancer.To listen to more podcasts from ASCO, visit asco.org/podcasts.

The ESMO Congress 2022 took place in Paris from September 9 to 13. In this episode, we highlight key research presented at the meeting. We'll first hear from the presenting author of Abstract LBA1 on the effect of air pollutants on the risk of non–small cell lung cancer. Then, we'll hear from a researcher on the SWOG S1801 team on the benefits of different therapeutic strategies using pembrolizumab in patients with advanced melanoma. Finally, we'll hear about the results of the IMmotion 010 study of adjuvant atezolizumab for renal cell carcinoma post-nephrectomy.To listen to more podcasts from ASCO, visit asco.org/podcasts.

This week, we're covering the FDA approval of pemigatinib for patients with myeloid or lymphoid neoplasms and an FGFR1 rearrangement. We'll also discuss a long-term update from the STAMPEDE trial of radiotherapy in prostate cancer.Coverage of stories discussed this week on ascopost.com:FDA Approves Pemigatinib for Patients With Myeloid/Lymphoid Neoplasms and FGFR1 RearrangementLong-Term Benefit of Radiotherapy Confirmed in Advanced Prostate Cancer: STAMPEDE Trial Follow-upTo listen to more podcasts from ASCO, visit asco.org/podcasts.

In this episode, we're featuring two speakers presenting data from the European Hematology Association 2022 Congress, focusing on findings in acute myeloid leukemia and diffuse large B-cell lymphoma.To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we're featuring discussions about data in colorectal cancer that were presented at the 2022 ASCO Annual Meeting. Dr. Michael Overman, of The University of Texas MD Anderson Cancer Center, speaks with two presenters about guiding therapy with circulating tumor DNA and refining treatment strategies for RAS wild-type metastatic disease.To listen to more podcasts from ASCO, visit asco.org/podcasts.

Dr. Courtney DiNardo, of The University of Texas MD Anderson Cancer Center, sat down with two colleagues at the 2022 ASCO Annual Meeting to discuss data presented in leukemia. On this episode of the podcast, we're featuring Dr. DiNardo's conversations.To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we're featuring discussions on lung cancer that took place at the 2022 ASCO Annual Meeting. They were led by Dr. Gilberto de Lima Lopes, Jr, of the Sylvester Comprehensive Cancer Center at the University of Miami. The first focuses on data from a study of a novel bispecific antibody in patients with non–small cell lung cancer that exhibits the MET exon 14 skipping mutation. The second focuses on an analysis of patients with lung cancer treated with chemoimmunotherapy regimens.To listen to more podcasts from ASCO, visit asco.org/podcasts.

At the 2022 ASCO Annual Meeting, Dr. Ann Partridge, of Dana-Farber Cancer Institute, discussed trends in breast cancer with several colleagues. On this episode, we're featuring two of those conversations: one on antibody-drug conjugates, and another on endocrine therapy plus ribociclib for progressive breast cancer.To listen to more podcasts from ASCO, visit asco.org/podcasts.

In this episode, we're featuring two conversations focusing on gynecologic oncology, both led by Dr. Ursula Matulonis, of Dana-Farber Cancer Institute. Dr. Matulonis, along with two colleagues, reviews data presented at the 2022 ASCO Annual Meeting in ovarian, primary peritoneal, and fallopian tube cancer.To listen to more podcasts from ASCO, visit asco.org/podcasts.

In this episode, we're featuring two conversations from leaders in the field of genitourinary oncology. These discussions go over long-term findings in prostate cancer and urothelial carcinoma, and were both presented at the 2022 ASCO Annual Meeting. To listen to more podcasts from ASCO, visit asco.org/podcasts.

In this episode, we continue to highlight research presented at the 2022 ASCO Annual Meeting. We'll first hear a discussion between two researchers on Plenary Abstract LBA1, which may establish a standard first-line combination regimen for patients with RAS wild-type and left-sided metastatic colorectal cancer. Then, we'll hear about a study that highlighted the need to increase participation in clinical trials amongst Black women with metastatic breast cancer. To listen to more podcasts from ASCO, visit asco.org/podcasts.

In this episode, we'll hear about results from the phase III DETERMINATION trial in multiple myeloma, and a study that sought to determine when radiotherapy may be avoided after breast-conserving surgery.To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we're reviewing two studies, including one plenary presentation, presented at the 2022 ASCO Annual Meeting. To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we're continuing our coverage of high-impact research presented at the 2022 ASCO Annual Meeting, focusing on major studies in breast cancer and mantle cell lymphoma.To listen to more podcasts from ASCO, visit asco.org/podcasts.

The 2022 ASCO Annual Meeting took place last week in Chicago. This week, we're featuring conversations on two high-profile studies in breast cancer and colon cancer presented at the meeting.To listen to more podcasts from ASCO, visit asco.org/podcasts.

Last week, the FDA approved treatments for esophageal cancer and follicular lymphoma. On this episode, we'll review the data supporting those approvals and hear from researchers involved in the trials investigating the efficacy of these regimens. Coverage of stories discussed this week on ascopost.com:FDA Approves Two Nivolumab-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell CarcinomaFDA Approves Tisagenlecleucel for Adult Patients With Relapsed or Refractory Follicular LymphomaTo listen to more podcasts from ASCO, visit asco.org/podcasts.

This week, we're covering the FDA approval of a doublet therapy in certain populations of patients with newly diagnosed acute myeloid leukemia. Then we'll hear about a comparison study of treatments for patients with metastatic breast cancer and brain metastases.Coverage of stories discussed this week on ascopost.com:FDA Approves Ivosidenib/Azacitidine for Certain Patients With Newly Diagnosed AMLEtirinotecan Pegol vs Physician's Choice of Chemotherapy for Patients With Metastatic Breast Cancer and Brain MetastasesTo listen to more podcasts from ASCO, visit asco.org/podcasts.

The Society of Gynecologic Oncology Annual Meeting on Women's Cancer was held recently in Phoenix, Arizona. On this episode, we'll hear from two researchers who presented data at the meeting on ovarian and cervical cancers.To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we'll be discussing an updated overall survival analysis from the MONALEESA-3 trial presented at the ESMO Breast Cancer Congress 2022. Then, we'll hear from a researcher about the current state of cancer research and anticipated trends in the field.Coverage of stories discussed this week on ascopost.com:Updated Overall Survival Results From MONALEESA-3 Show Improved Overall Survival in Patients With HR-Positive/HER2-Negative Breast CancerTo listen to more podcasts from ASCO, visit asco.org/podcasts.

On May 4, the FDA approved fam-trastuzumab deruxtecan-nxki for pretreated adult patients with unresectable or metastatic HER2-positive breast cancer. We highlight findings from the DESTINY-Breast03 trial that led to the regular approval, and also hear from Dr. Sara Hurvitz, of the University of California, Los Angeles Jonsson Comprehensive Cancer Center, who discussed the trial results with The ASCO Post at the 2021 San Antonio Breast Cancer Symposium.Coverage of stories discussed this week on ascopost.com:FDA Grants Regular Approval to Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Breast CancerTo listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we'll continue our coverage of the American Association for Cancer Research, or AACR, Annual Meeting. We'll hear from three specialists on the future of cancer research and treatment; the development of novel therapeutic strategies to target DNA damage response; and an overview of the FDA's accelerated approval program.To listen to more podcasts from ASCO, visit asco.org/podcasts.

The American Association for Cancer Research, or AACR, Annual Meeting took place from April 8 to 13 in New Orleans. The AACR Annual Meeting brings together the cancer research community to share the latest advances in cancer science and medicine, from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy. On this episode of the podcast, we'll hear from three researchers who presented data at the meeting.To listen to more podcasts from ASCO, visit asco.org/podcasts.

The NCCN 2022 Annual Conference took place from March 30 to April 1 as a virtual event. Designed to meet the educational needs of the interprofessional oncology care team, the conference offered more than 30 educational sessions featuring the latest advances and experts in oncology care. On this episode of the podcast, we'll hear from three speakers who discussed recent advances in cancer care in their respective fields.To listen to more podcasts from ASCO, visit asco.org/podcasts.

In this week's episode, we are discussing two recent FDA approvals—one for prostate cancer, and the other for endometrial cancer. The radioconjugate lutetium Lu-177 vipivotide tetraxetan was approved for the treatment of adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. Pembrolizumab was approved as a single agent for patients with advanced endometrial carcinoma that is microsatellite instability–high or mismatch repair–deficient as determined by an FDA-approved test; eligible patients have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.Coverage of stories discussed this week on ascopost.com:FDA Approves Radioligand for Metastatic Castration-Resistant Prostate CancerFDA Approves Pembrolizumab for Advanced Endometrial CarcinomaTo listen to more podcasts from ASCO, visit asco.org/podcasts.

In this week's episode, we'll discuss a recent FDA approval in germline BRCA-mutated, HER2-negative, high-risk early breast cancer. Then, we'll hear about the publication of final overall survival results from the MONALEESA-2 trial, which evaluated the efficacy of the addition of ribociclib to letrozole in the first-line treatment of postmenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer.Coverage of stories discussed this week on ascopost.com:FDA Approves Olaparib for Adjuvant Treatment of High-Risk Early Breast CancerFinal Overall Survival Analysis of MONALEESA-2: Addition of Ribociclib to Letrozole in Postmenopausal Women With HR-Positive, HER2-Negative Advanced Breast CancerTo listen to more podcasts from ASCO, visit asco.org/podcasts.

In this week's episode, we'll discuss a recent U.S. Food and Drug Administration (FDA) approval in the early-stage non–small cell lung cancer setting. Then, we'll hear about a study presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium that investigated methods for the de-escalation of radiation therapy for oropharyngeal cancer.Coverage of stories discussed this week on ascopost.com:FDA Approves Neoadjuvant Nivolumab and Platinum Doublet Chemotherapy for Early-Stage NSCLCMidtreatment Imaging De-escalates Therapy for Half of Patients With Oropharyngeal CancerTo listen to more podcasts from ASCO, visit asco.org/podcasts.

The 2022 Multidisciplinary Head and Neck Cancers Symposium took place from February 24 to 26 in Phoenix, Arizona. The meeting provided the most up-to-date information on multidisciplinary therapies, clinical research, treatment strategies, supportive care, and scientific breakthroughs in head and neck cancer. On this episode of the podcast, we'll hear from three authors who presented their research at the meeting.To listen to more podcasts from ASCO, visit asco.org/podcasts.